Basit öğe kaydını göster

dc.contributor.authorAktas, Burak Y.
dc.contributor.authorAktas, Ozge Ozturk
dc.date.accessioned2021-06-03T05:20:01Z
dc.date.available2021-06-03T05:20:01Z
dc.date.issued2019
dc.identifier.issn0028-4793
dc.identifier.urihttp://dx.doi.org/10.1056/NEJMc1912185
dc.identifier.urihttp://hdl.handle.net/11655/23963
dc.description.abstractTo the Editor: In the randomized, placebo-controlled Vitamin D and Type 2 Diabetes (D2d) trial involving persons at risk for type 2 diabetes, Pittas et al. (Aug. 8 issue)(1) found that vitamin D-3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo. Investigators emphasized that the trial was planned not only for participants with vitamin D insufficiency, given ethical considerations. Although the mean baseline vitamin D levels are well balanced between the trial groups and above insufficiency limits, more than 20% of the participants in the placebo group . . .
dc.language.isoen
dc.relation.isversionof10.1056/NEJMc1912185
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleVitamin D Supplementation And Prevention Of Type 2 Diabetes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalNew England Journal Of Medicine
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume381
dc.identifier.issue18
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States